SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is seeing a significant surge amid widespread rumors of an impending partnership with Novo Nordisk to sell obesity drugs on its platform, fueling intense short squeeze speculation due to high short interest and renewed optimism around its expanding peptide offerings.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending following a surprise partnership with Hims & Hers to sell obesity drugs, a move the community views as trapping shorts and signaling a major turnaround. This development, coupled with rapidly accelerating adoption of its oral Wegovy and a recent FDA crackdown on compounded GLP-1s, has many calling the stock a generational buying opportunity despite past competitive pressures.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community celebrates the imminent departure of a prominent FDA official, widely seen as a significant barrier to the approval of its Duchenne Muscular Dystrophy therapy, Deramiocel. This development, coupled with high anticipation for a late-breaking Phase 3 data presentation at a major medical conference next week, is fueling intense bullish sentiment and expectations for a rapid regulatory decision.

Seeker is building a decentralized mobile ecosystem designed to challenge entrenched mobile incumbents through its TEEPin network architecture and community governance. It aims to solve the pain points of centralized app store gatekeeping, lack of developer freedom, and restricted user access to crypto applications. The vision is to create a community-owned platform with decentralized governance, no gatekeepers, direct developer-user access, and TEEPin security architecture.

Seeker

Seeker ($SKR) is gaining significant attention and volume following new listings on major exchanges, positioning it as the utility token for the Solana Mobile "Seeker" smartphone ecosystem. The community is actively discussing breaking key resistance levels with strong bullish conviction, though some caution about potential selling pressure from recent airdrops and staking unlocks.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group ($DJT) is trending amidst intense community discussion following the release of new Epstein files containing sexual assault allegations against Donald Trump, alongside widespread concern over the ongoing conflict with Iran and its perceived negative impact on the economy and gas prices.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is seeing immense upward pressure as escalating geopolitical tensions in the Middle East have effectively disrupted shipping through the critical Strait of Hormuz, causing widespread concerns about global oil supply. The community is actively discussing the potential for significantly higher crude prices, viewing the situation as a genuine supply 'plumbing break' rather than just a fleeting fear-driven rally.

SSgA Active Trust - State Street SPDR Dow Jones Industrial Average ETF Trust

The SPDR Dow Jones Industrial Average ETF (DIA) is highly volatile amid escalating Middle East tensions driving oil prices higher and intensifying inflation concerns, leading the community to debate potential market downturns and Federal Reserve policy implications.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network (BNAI) is trending as a recent AI licensing partnership in Africa sparks widespread discussion about a potential massive short squeeze, driven by a low float, increasing short interest, and extremely high borrow rates. The stock's ability to remain green amidst broader market volatility is also a key point of community excitement.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending as the community anticipates a more permissive regulatory environment for its gene therapies following the imminent departure of a prominent FDA official, an event coupled with the CEO's announced retirement sparking M&A speculation and excitement for upcoming pivotal clinical data.

Rithm Capital Corp. engages in the provision of real estate, credit, and financial services. It operates through the following segments: Origination and Servicing, Investment Portfolio, Residential Transitional Lending, Asset Management, and Corporate. The Origination and Servicing segment includes residential mortgage loans underlying mortgage servicing right assets as well as those sub-service for third parties. The Investment Portfolio segment consists of residential mortgage loans, SFR properties, consumer loans, Non-Agency RMBS, Excess MSRs and servicer advance investments. The Residential Transitional Lending segment competes for both experienced sponsors, including developers and investors in residential real estate, and attractive lending opportunities based on several factors. The Asset Management segment focuses on the wholly owned subsidiaries, Sculptor, and RCM Manager. The company was founded on September 26, 2011 and is headquartered in New York, NY.

Rithm Capital Corporation

Anticipation of Rithm Capital's inclusion in the S&P SmallCap 600 is driving current interest, with the community highlighting expected "forced buying" from index funds. This is further fueled by discussions around the company's strong performance, recent strategic acquisitions, and the long-term potential of a C-Corp conversion to unlock its perceived undervaluation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

PCSA Stock Soars on Upbeat Clinical Update From Breast Cancer Study

Processa Pharmaceuticals stock jumps 122% after a phase II update shows NGC-Cap delivers higher active metabolite exposure with comparable safety in breast cancer.

Why Is Small-Cap Processa Pharmaceuticals Stock Rallying After Breast Cancer Trial Data?

Processa Pharmaceuticals' stock jumps after Phase 2 data show higher capecitabine exposure without added toxicity in metastatic breast cancer patients.read more...

<ul class="summary-bullets"><li>Hut 8 shares were up more than 11% in Wednesday’s midday trade after the company announced that it is building an AI data center for Anthropic.</li><li>Processa Pharmaceuticals' shares were up nearly 95% after early Phase 2 data showed that its NGC-Cap therapy boosts capecitabine exposure without added side effects compared with standard treatment.</li><li>Recursion Pharmaceuticals shares jumped over 16% by midday Wednesday after Morgan Stanley upgraded the stock to ‘Overweight’ and raised its price target to $11, citing strong efficacy for its drug REC-4881.</li></ul>U.S. equities were in the red in Wednesday’s midday trade as investors exercised caution amid a broader decline in artificial intelligence stocks, with Oracle and Broadcom shares declining by nearly 5% each.The&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which mirrors the S&amp;P 500 index, was down 0.68% at the time of writing, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ), which mirrors the Nasdaq 100 index, declined 1.28%. The&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA), which tracks the Dow Jones Industrial Average, fell 0.2%.<h2 class="st-heading-2">Here are the top stocks making the biggest moves in Wednesday’s midday trade:</h2><a href="https://stocktwits.com/symbol/ORCL">Oracle Corp. (ORCL)</a>Oracle shares were down over 5% in Wednesday’s midday session after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/oracle-s-ai-expansion-hits-snag-as-key-investor-pulls-back-report/cLeO1HSREqa">faced</a> a setback in its AI data center expansion efforts after Blue Owl Capital reportedly withdrew from a $10 billion investment in the company’s new facility in Saline Township, Michigan.<a href="https://stocktwits.com/symbol/ORCL">ORCL stock</a> is up 8% year-to-date.<a href="https://stocktwits.com/symbol/HUT">Hut 8 Corp. (HUT)</a>Hut 8 shares were up more than 11% in Wednesday’s midday trade after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hut-shares-soar-over-24-percet-today-whats-the-deal-involving-google-and-anthropic/cLeO1aZREqJ">announced</a> that it is building an AI data center for Anthropic, and that it had signed a 15-year, $7 billion lease with Fluidstack. The company added that the lease would be worth up to $17.7 billion if all renewal options are exercised.<a href="https://stocktwits.com/symbol/HUT">HUT stock</a> is up 100% year-to-date.<a href="https://stocktwits.com/symbol/PCSA">Processa Pharmaceuticals Inc. (PCSA)</a>Processa Pharmaceuticals share price nearly doubled, hovering at gains of 95% in Wednesday’s midday trade after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-processa-pharmaceuticals-stock-surge-160-today/cLeOVJlREqV">stated</a> that its early Phase 2 trial data showed that its NGC-Cap therapy significantly increases exposure to capecitabine cancer-killing drug metabolites without increasing the severity of side effects compared to standard monotherapy capecitabine therapy.<a href="https://stocktwits.com/symbol/PCSA">PCSA stock</a> is down 73% year-to-date.<a href="https://stocktwits.com/symbol/RXRX">Recursion Pharmaceuticals Inc. (RXRX)</a>Recursion Pharmaceuticals shares were up over 16% in Wednesday’s midday session after Morgan Stanley upgraded the stock to ‘Overweight’ from ‘Neutral’, according to TheFly. The firm also hiked its price target for the RXRX stock to $11 from $10, citing “strong and durable” efficacy in familial adenomatous polyposis from the company's small-molecule drug, REC-4881.<a href="https://stocktwits.com/symbol/RXRX">RXRX stock</a> is down 28% year-to-date.<a href="https://stocktwits.com/symbol/UDMY">Udemy Inc. (UDMY)</a>Udemy shares were up more than 22% in Wednesday’s midday session after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cour-udmy-stock-premarket-coursera-udemy-announce-merger/cLeOKUtREq4">announced</a> a merger with Coursera Inc. (COUR), with an implied equity value of the combined entity of approximately $2.5 billion.<a href="https://stocktwits.com/symbol/UDMY">UDMY stock</a> is down 20% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/waller-fed-chair-odds-surge-after-dovish-comments/cLeOjlBREqg">Waller's Odds For Fed Chair Nomination Surge After The Fed Governor's Dovish Comments On Rate Cuts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A bull statue and a bear statue stand outside the Frankfurt Stock Exchange on April 7, 2025 in Frankfurt, Germany

Oracle, Hut 8, Processa Pharmaceuticals, Recursion Pharmaceuticals, Udemy: Stocks Making The Biggest Moves Today

Oracle shares were down over 5% in Wednesday’s midday session after Blue Owl Capital reportedly withdrew from a $10 billion investment in the company’s new facility in Saline Township, Michigan.

Equity

<ul class="summary-bullets"><li>Processa plans to complete enrollment for the formal 20-patient interim analysis by the end of the first quarter of 2026.</li><li>The company’s stock also began trading on a 1-for-25 reverse stock split basis on Wednesday.</li><li>Trading in PCSA shares was halted multiple times today, according to Nasdaq data.</li></ul>Processa Pharmaceuticals Inc. (PCSA) surged over 160% on Wednesday, after the company announced that early Phase 2 data showed that its Next Generation Cancer (NGC) therapy delivered higher levels of cancer-fighting metabolites in patients with advanced or metastatic breast cancer.The company’s stock also began trading on a 1-for-25 reverse stock split basis on Wednesday. Trading in <a href="https://stocktwits.com/symbol/PCSA">PCSA shares</a> was halted multiple times on Wednesday, according to Nasdaq data.<h2 class="st-heading-2">Phase 2 Study Results&nbsp;</h2>Preliminary data from the first 16 of 19 enrolled patients indicated that NGC-Cap significantly increases exposure to capecitabine’s cancer-killing metabolites compared with standard capecitabine monotherapy without increasing the severity of side effects seen with standard treatment. The company believes the balance could improve outcomes for patients with advanced breast cancer.Nineteen patients were randomized to receive either NGC-Cap (150 mg twice daily) or standard Mono-Cap (1,000 mg/m² twice daily). Early safety data from the first 16 patients show higher exposure to cancer-killing metabolites in the NGC-Cap group.While more patients in the NGC-Cap group experienced side effects related to these metabolites, the severity was similar to that in the Mono-Cap group.&nbsp;Processa plans to complete enrollment for the formal 20-patient interim analysis, which will include both safety and efficacy data, by the end of the first quarter of 2026. The company expects to report the interim analysis in early 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits flipped to ‘extremely bullish’ from ‘bearish’, amid ‘extremely high’ message volumes. PCSA was the top trending ticker on Stocktwits.<figure class="image"><img style="aspect-ratio:922/93;" src="https://news.stocktwits-cdn.com/PCSA_png_df422e4216.webp" alt="PCSA.png" width="922" height="93"><figcaption>PCSA's Sentiment Meter and Message Volumes at 11:30 a.m. ET on Dec. 17, 2025 | Source: Stocktwits</figcaption></figure>One Stocktwits user expects further upside to the stock.<stembedurl>https://stocktwits.com/AJWW316/message/639440673</stembedurl>Read also: <a href="https://stocktwits.com/news-articles/markets/equity/uwm-holdings-to-acquire-two-harbors-investment-in-1-3-b-deal/cLeOjLYREqf">UWM Holdings To Acquire Two Harbors Investment In $1.3B Deal - How Much Of The Combined Company Will UWM Shareholders Own?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

Why Did Processa Pharmaceuticals Stock Surge 160% Today?

The company announced that early Phase 2 data showed that its NGC therapy increased cancer-fighting metabolites in patients with advanced breast cancer.

Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its main product candidate is PCS499, which is intended for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on March 29, 2011 and is headquartered in Vero Beach, FL.

Current Price	$2.83
Prev Close	$2.85
Open	$2.88
Dividend Yield	0.00%
50-Day Moving Average	$2.84
Beta	0.80
Avg. Volume	49,391.12
PE Ratio	-0.08

52-Week High	$19.63
52-Week Low	$1.76
Market Capitalization	$6.47M
EPS (Annual)	-$96.82
Price to Book	1.03
Revenue Per Employee	$0.00

PCSA
Processa Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PCSA News

PCSAProcessa Pharmaceuticals Inc